Quercetin

Quercetin is a plant flavonol, common in onions, apples, and capers. On its own, it has decades of antioxidant and anti-inflammatory research behind it, most of it inconclusive for hard clinical outcomes in healthy adults. A 2025 systematic review and meta-analysis of human bioavailability studies found absorption varies severalfold depending on the glycoside form and food matrix, which is one reason quercetin trials produce inconsistent results even at similar nominal doses [1].

The reason quercetin now shows up in longevity discussions has almost nothing to do with quercetin alone. It is one half of dasatinib plus quercetin (D+Q), the senolytic combination first shown by Zhu and colleagues in 2015 to selectively kill senescent cells and improve physical function in mouse models of aging and disease. Quercetin's contribution in that combination is modest by itself. In a 2024 human ex vivo study on osteoarthritic cartilage, D+Q eliminated senescent chondrocytes and reduced SASP factors IL-6 and CXCL1, but the researchers explicitly found the chondroanabolic effect came mainly from dasatinib, not quercetin: quercetin alone did not promote cartilage-building gene expression [2]. That is an important negative finding inside a positive-looking study.

The first human D+Q trial to report results, a small open-label study in patients with idiopathic pulmonary fibrosis (Justice et al., 2019, not further detailed here beyond citation elsewhere), showed reduced senescent cell burden markers. Larger controlled human trials of D+Q for general aging outcomes are still in early stages; ClinicalTrials.gov lists at least one trial (NCT04313634) targeting cellular senescence with D+Q in adults with diabetic kidney disease [3]. Results from that kind of trial, not observational reports, are what would establish whether periodic D+Q dosing changes hard outcomes in humans.

What the evidence does not show: that quercetin taken alone, as a daily antioxidant supplement, does anything measurable for human aging biomarkers. Most positive senolytic data attach to the combination, tested intermittently (a few days per month), not continuous quercetin megadosing. Long-term mouse data on quercetin monotherapy for senescence clearance are weaker than for the pair.

Blueprint does not list quercetin, or D+Q, among Bryan Johnson's current publicly documented supplements; his senolytic of choice, per third-party protocol breakdowns, is fisetin. That is a useful data point: even a self-experimenter who tracks biomarkers obsessively did not settle on quercetin as his senolytic.

Critics of senolytic enthusiasm, including gerontologist S. Jay Olshansky, have argued publicly that senescent-cell clearance in mice does not reliably predict comparable gains in healthy human aging, given the mouse models used are often progeroid or disease-accelerated rather than naturally aged. That critique applies to the D+Q literature broadly, quercetin included.

The honest takeaway: quercetin's best evidence is borrowed from a drug combination it is only half of, tested intermittently, not as a standalone daily antioxidant. Buying quercetin alone and taking it every day is not the same intervention the senescence literature actually tested.

2026: Senolytics Shift From Broad-Spectrum to Precision

A review published in Nature Aging traced the evolution of senolytic research from first-generation compounds (navitoclax, dasatinib+quercetin) to next-generation precision senotherapeutics [1]. The review noted that first-generation senolytics had broad off-target effects, and the field is moving toward more targeted approaches. For supplement consumers, quercetin and fisetin are first-generation senolytics with broad mechanisms. The review suggests that more targeted approaches may be more effective, but quercetin remains the most-studied senolytic in human trials.

A new clinical trial (NCT07466420) is studying quercetin efficacy in patients with fibrotic interstitial lung diseases [2].

Products with this: Quercetin, Quercetin Phytosome